

# Daniel H Kwon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2792567/publications.pdf>

Version: 2024-02-01

14  
papers

98  
citations

1478505

6  
h-index

1372567

10  
g-index

14  
all docs

14  
docs citations

14  
times ranked

185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
2	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	4.1	15
3	Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. <i>JCO Oncology Practice</i> , 2021, 17, e377-e385.	2.9	14
4	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	5.0	12
5	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	1.9	9
6	COVID-19 outcomes in patients with cancer: Findings from the University of California health system database. <i>Cancer Medicine</i> , 2022, 11, 2204-2215.	2.8	6
7	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	6
8	Gastric neuroendocrine tumors: management and challenges. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, Volume 7, 31-37.	5.5	4
9	Down-regulation of <i>ADRB2</i> expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16.	1.6	4
10	Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era. <i>JCO Oncology Practice</i> , 2021, 17, 161-163.	2.9	2
11	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
12	Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	1
13	Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials. <i>European Urology</i> , 2020, 78, 854-855.	1.9	0
14	Reply to R. Kebudi et al. <i>JCO Oncology Practice</i> , 2021, 17, 364-364.	2.9	0